Welcome to our dedicated page for BOUNDLESS BIO news (Ticker: BOLD), a resource for investors and traders seeking the latest updates and insights on BOUNDLESS BIO stock.
Boundless Bio, Inc. develops clinical-stage oncology therapies aimed at oncogene-amplified tumors through extrachromosomal DNA (ecDNA) biology. Its news centers on BBI-940, an oral, selective Kinesin degrader and ecDNA-directed therapeutic candidate, including KOMODO-1 clinical development, preclinical AACR data, FDA IND acceptance, and cancer-model results.
Company updates also cover financial results, cash runway and capital allocation, conference appearances, and portfolio prioritization, including the discontinued POTENTIATE program that combined BBI-355, a CHK1 inhibitor, with BBI-825, an RNR inhibitor.
Summary not available.
Summary not available.